News
6h
Zacks Investment Research on MSNNovo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...
This health crisis is largely attributed to sedentary lifestyles, excessive consumption of processed and fast food, and ...
Locally produced versions of drugs like Semaglutide are helpful for patients with obesity and diabetes, but unprescribed use raises concerns ...
Pharma giant Eli Lilly’s weight loss drug Mounjaro is priced between Rs. 10,000- ₹15,000 in India making it inaccessible to a ...
The popularity of weight loss drugs has caused a shortage in recent years, but how effective are they at helping with food ...
Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...
The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...
People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...
Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...
Our Bureau, Mumbai Monday, May 12, 2025, 14:45 Hrs [IST] ...
Wegovy can cause some side effects. The most common side effects of semaglutide are nausea, vomiting, and diarrhoea. Other ...
23d
Best Life on MSNWeight-Loss Drugs Could Reduce Risk of Death by 50%—But Not OzempicOzempic and Wegovy have taken the back seat.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results